Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare.

Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence.

Tempus was founded in 2015 by Eric Lefkofsky and Brad Keywell. The company is headquartered in Chicago, Illinois, with offices in New York and San Francisco, California.

Tempus has developed novel technology that generates, collects, structures, and analyzes vast amounts of data and merged with the power of AI. This enables hysicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Tempus' genomic tests analyze somatic and germline information across DNA, RNA, and proteomic data to help identify treatment options tailored for the individual. The company's proprietary trial matching software utilizes NGS as well as EMR integrations to identify patients that match to the right trial at the right time.

Tempus' platform is used by providers, lifescience companies, & patients to make data accessible and deploy AI at scale. Some of its recent collaborations include GSK, Kartos Therapeutics, Children’s Oncology Group (COG), Eli Lilly and Company, Intermountain Healthcare, among others.

Tempus is backed by Google, NEA, Baillie Gifford, Franklin Templeton, Ares Management, T. Rowe Price, Novo Holdings, Revolution, and others. The company raised $275M through a combination of equity and equity round on Oct 20, 2022. This brings Tempus' total funding to $1.3B to date. Tempus was last valued at $8.1B from their previous financing in Dec 2020.